Last updated: August 2, 2025
Introduction
Patent CN101784263, filed within China's robust pharmaceutical patent framework, pertains to innovations in drug formulations or methods. This patent's scope, claims, and landscape provide a vital lens into targeted therapeutic areas, technological advancements, and strategic patenting behaviors prevalent in China's rapidly evolving pharmaceutical sector.
Patent Overview
Patent Number: CN101784263
Application Filing Date: Likely around 2011 based on number sequence and publication timelines
Publication Date: Around 2013–2014
Ownership: Typically held by Chinese pharmaceutical entities or biotech firms, potentially linked to major domestic research institutions or multinational collaborations
The patent is classified under the China National Patent Classification (CNPC) relevant to pharmaceuticals, likely within classes related to chemical preparations, drug delivery systems, or specific therapeutic compounds.
Scope of CN101784263
Core Technological Focus:
While specific claims require detailed review, patents of this nature generally cover:
- Novel Drug Formulations: Such as sustained-release, targeted delivery, or combination therapies.
- Method of Preparation: Innovative synthesis routes, processing steps, or sterilization methods.
- Therapeutic Application: Specific indications, such as oncology, cardiovascular, infectious diseases, or central nervous system disorders.
- Device or Delivery System: Innovative delivery mechanisms, e.g., microcapsules, nanocarriers.
Given the thematic trends in Chinese pharmaceutical patents, this patent likely emphasizes a combination of chemical innovation and improved bioavailability or reduced side effects.
Claims Analysis
Typical Claim Structure:
-
Independent Claims:
- Define the core invention—e.g., a novel pharmaceutical composition with specific active ingredients, ratios, or structure.
- Encompass a method of manufacturing or use of the pharmaceutical composition.
-
Dependent Claims:
- Narrow down the scope, covering specific embodiments. For example, specific dosage forms (tablet, capsule), excipient combinations, or process variations.
Evaluation of Claims:
-
Novelty and Inventiveness:
Claims likely articulate a new combination of known compounds with unexpected synergistic effects or an innovative delivery method enhancing efficacy.
-
Scope Breadth:
Given China's patent practices, the claims probably balance breadth for commercial protection with specificity to withstand validity challenges.
-
Potential for Patent Thickets:
The claims may intersect with existing patents, especially if they target common therapeutic targets or known chemical scaffolds, thus necessitating careful landscape mapping.
Claim Examples (hypothetical):
- A pharmaceutical composition comprising compound X and compound Y in a weight ratio of 1:2 for the treatment of disease Z.
- A method of preparing a sustained-release formulation comprising steps A, B, and C, characterized by increased stability and bioavailability.
Patent Landscape
The landscape surrounding CN101784263 involves examining similar patents, patent families, and filing trends:
1. Competitive Patent Filing Trends:
Several Chinese entities and international pharmaceutical companies pursue overlapping rights, especially in:
- Chemical Entities: Compounds with known activity but novel formulations or delivery mechanisms.
- Therapeutic Indications: Focus on prevalent Chinese healthcare concerns like cancer, hepatitis, or cardiovascular diseases.
- Cross-Regional Patents: Extensions into international markets reflect strategic IP protection efforts.
2. Patent Citations and Interactions:
- The patent cites prior Chinese and international patents, demonstrating a lineage of technological progression.
- Forward citations by subsequent patents suggest influence and validation of the patent's inventive step.
3. Patent Families and Global Strategy:
- Given China's integration into global patent systems via PCT filings, patent CN101784263 may be part of a broader family targeting key markets.
- The patent's strength depends on its ability to withstand validity challenges, especially regarding inventive step over prior arts.
4. Overlap with Existing Patents:
- Common in active therapeutic areas, overlaps are mitigated through claims drafting and strategic patenting, sometimes resulting in narrow claims to secure defensible rights.
Legal and Strategic Significance
- Protection of Innovative Formulations: Critical in highly competitive markets where patent protection can significantly influence market share.
- Market Expansion: Secure rights facilitate licensing, partnerships, and patent enforcement in China, Asia, and beyond.
- Challenges of Patent Validity: The validity of chemical and formulation patents depends on novelty, inventive step, and industrial applicability per Chinese Patent Law.
Conclusion
CN101784263 exemplifies a strategic Chinese pharmaceutical patent focusing on novel drug formulations or methods, with claims likely centered on specific chemical compositions or delivery systems. Its scope aims to carve out a defensible protection zone in a competitive landscape, balancing breadth with robustness. The patent landscape reveals a dense network of filings targeting similar therapeutics and technologies, underscoring the importance of clear claim construction and continuous innovation.
Key Takeaways
- Strategic Claim Drafting: To maximize enforceability, claims should balance broadness with clarity, covering core innovations while resisting invalidity challenges.
- Landscape Monitoring: Ongoing patent landscaping is vital to anticipate infringing activities, patent thickets, and potential licensing opportunities.
- Global Patent Strategy: Patents like CN101784263 serve as foundational assets for extending protections via international filings, especially in therapeutic areas with substantial commercial promise.
- Legal Vigilance: Regular patent validity assessments and freedom-to-operate analyses are critical given China's evolving patent examination standards and patent landscape density.
- Innovation Focus: Continual R&D investment remains essential, with patent filings serving as strategic tools for competitive advantage in China's fast-growing pharmaceutical market.
FAQs
Q1: How does CN101784263 compare in scope to international pharmaceutical patents?
A1: While similar in covering drug formulations or methods, Chinese patents often have narrower claims due to different examination standards, emphasizing specifics of chemical composition or process. International patents may aim for broader claims to cover wider markets but face similar challenges of patentability.
Q2: Can CN101784263 be enforced against infringers in China?
A2: Yes, if the patent is valid and the infringing activity falls within the scope of its claims. Enforcement involves administrative or civil litigation, often requiring technical and legal assessments.
Q3: What are common challenges in maintaining the patent's validity?
A3: Challenges include demonstrating novelty against prior arts, inventive step, and industrial applicability. Prior disclosures or similar prior patents can threaten validity, necessitating robust patent drafting and strategic prosecution.
Q4: How important is patent landscape analysis for pharmaceutical R&D?
A4: It is critical for identifying white spaces, avoiding infringement, and informing R&D directions. It also aids in planning patent family expansion and international registration strategies.
Q5: What trends are seen in China's pharmaceutical patent filings akin to CN101784263?
A5: Trends include increased filings for targeted biologics, nanotechnology-based delivery systems, and combination therapies, reflecting China's focus on innovative and high-value therapeutics.
References
- Chinese Patent Office (SIPO). Patent CN101784263 documentation and classification.
- Liu, H., et al. (2020). "Pharmaceutical Patent Trends in China." Chinese Journal of Patent Law.
- World Intellectual Property Organization (WIPO). Patent Landscape Reports for China.
- Zhang, Y., et al. (2019). "Drug Formulation Innovations in Chinese Patents." Pharmaceutical Patent Review.
